Godavari Drugs Ltd
NSE: BSE: 530317
₹127.90
(1.99%)
Sun, 24 May 2026, 00:29 am
Market Cap936.42M
PE Ratio26.09
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KGodavari Drugs Analysis
dividend
- Unable to evaluate Godavari Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Godavari Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Godavari Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Godavari Drugs is profitable, therefore cash runway is not a concern.
- Godavari Drugs is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2.3x debt.
- Godavari Drugs's cash and other short term assets cover its long term commitments.
- Debt is not well covered by operating cash flow (15.1%, less than 20% of total debt).
- The level of debt compared to net worth has increased over the past 5 years (31.5% vs 129.5% today).
- Interest payments on debt are not well covered by earnings (EBIT is 2x annual interest expense, ideally 3x coverage).
- Godavari Drugs's level of debt (129.5%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Godavari Drugs board of directors is about average.
- Mukund's remuneration is lower than average for companies of similar size in India.
- Mukund's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Godavari Drugs is not covered by any analysts.
- Godavari Drugs has significant price volatility in the past 3 months.
past
- Godavari Drugs's 1-year earnings growth exceeds its 5-year average (36.1% vs -23.9%)
- Godavari Drugs's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (36.1% vs 22.7%).
- Godavari Drugs's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
- Godavari Drugs used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Godavari Drugs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Godavari Drugs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- Godavari Drugs is good value based on assets compared to the IN Pharmaceuticals industry average.
- Godavari Drugs is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Godavari Drugs is good value based on earnings compared to the India market.
- BSE:530317 is up 19.4% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530317 is up 19.4% outperforming the market in India which returned 8% over the past month.
- Godavari Drugs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Godavari Drugs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- 530317 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 530317 underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Asset Management Companies
Popular Stocks
Indian Indices
Sector Wise Stocks
IPO
Share Market
Best MF Schemes
Platforms
Resources
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800